Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
The Ministry of Health, Labor and Welfare (MHLW) on December 28 granted conditional, time-limited approval for Nipro’s STR01, the first stem cell therapy for the treatment of spinal cord injury (SCI). Developed jointly by Nipro and Sapporo Medical University, STR01,…
To read the full story
Related Article
- Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- MHLW Panel Recommends Conditional Approval for Nipro’s Stem Cell Product for Spinal Cord Injury
November 26, 2018
BUSINESS
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
- Meiji Pharma Takes Stake in Lyric Bio to Back Next-Gen IVIg Manufacturing
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…